Renal Dysfunction at 12 Months Is Not Associated with Everolimus Exposure in De Novo Renal Transplant Recipients.

被引：0
|
作者：
Shihab, F. [1 ]
Qazi, Y. [2 ]
Mulgaonkar, S. [3 ]
McCague, K. [4 ]
Patel, D. [4 ]
Peddi, V. [5 ]
Shaffer, D. [6 ]
机构：
[1] Univ Utah, Salt Lake City, UT USA
[2] Univ Southern Calif, Los Angeles, CA USA
[3] Barnabas Hlth, W Orange, NJ USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Calif Pacific Med Ctr, San Francisco, CA USA
[6] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2016年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
B135
引用
收藏
页码：544 / 544
页数：1
相关论文
共 50 条
  • [1] Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients.
    Shihab, F.
    Qazi, Y.
    Mulgaonkar, S.
    McCague, K.
    Patel, D.
    Peddi, V.
    Shaffer, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 217 - 217
  • [2] Exposure to CsA, and not to everolimus, is associated with impaired renal function in de novo heart transplant recipients.
    Varnous, Shaida
    Livi, Ugolino
    Poncelet, Alain
    Delgado, Juan
    Vermes, Emmanuelle
    Li, Yulan
    Arizon, Jose
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 346 - 346
  • [3] EVEROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS
    Prokopenko, E. I.
    VESTNIK TRANSPLANTOLOGII I ISKUSSTVENNYH ORGANOV, 2010, 12 (02): : 74 - 81
  • [4] Preservation of Renal Function with Everolimus and Very Low Tacrolimus Exposure in De Novo Renal Transplant Recipients (RTxR) at 12 Months: The ASSET Study
    Pascual, J.
    Hene, R.
    Langer, R.
    Christiaans, M.
    Ciechanowski, K.
    Vilatoba, M.
    Dominguez, J.
    Wyzgal, J.
    Guerkan, A.
    Burgos, D.
    Vitko, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 502 - 502
  • [5] Everolimus-Facilitated Tacrolimus Minimization Preserves Renal Function in De Novo Renal Transplant Recipients.
    Shihab, F.
    Qazi, Y.
    Kaplan, B.
    Kim, D.
    Mulgaonkar, S.
    Peddi, V.
    Shaffer, D.
    Patel, D.
    McCague, K.
    Vincenti, F.
    TRANSPLANTATION, 2014, 98 : 538 - 539
  • [6] Significant Pharmacokinetic Interaction Between Everolimus and Tacrolimus in De Novo Renal Transplant Recipients.
    Chang, H. -P.
    Lee, C. -Y.
    Si, C. -C.
    Tsai, M. -K.
    Wu, F. -L. Lin
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 538 - 538
  • [7] De novo anorectal cancers in renal transplant recipients.
    Rudich, SM
    Buell, JF
    Beebe, TM
    Gross, TG
    Hanaway, MJ
    Alloway, RR
    Trofe, J
    Woodle, ES
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 433 - 433
  • [8] Everolimus and Very Low Exposure of Tacrolimus Provides Good Efficacy in De Novo Renal Transplant Recipients (RTxR) at 12 Months.
    Christiaans, M.
    Langer, R.
    Vitko, S.
    Hene, R.
    Tedesco, H.
    Cassuto, E.
    Rostaing, L.
    Asztalos, L.
    Wiecek, A.
    Henriques, A. C.
    Pascual, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 151 - 151
  • [9] Economic evaluation of everolimus with reduced-dose cyclosporine in de novo renal transplant recipients.
    Keown, P
    Ethgen, O
    Yang, XL
    Ricci, JF
    Kessabi, S
    Spaepen, S
    Annemans, L
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 504 - 504
  • [10] 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients
    Tedesco-Silva, Helio, Jr.
    Vitko, Stefan
    Pascual, Julio
    Eris, Josette
    Magee, John C.
    Whelchel, John
    Civati, Giovanni
    Campbell, Scott
    Alves-Filho, Gentil
    Bourbigot, Bernard
    Garcia, Valter Duro
    Leone, John
    Esmeraldo, Ronaldo
    Rigotti, Paolo
    Cambi, Vincenzo
    Haas, Tomas
    TRANSPLANT INTERNATIONAL, 2007, 20 (01) : 27 - 36
12345